Skip to content
Screener

Jade Biosciences JBIO Retained Earnings

Retained Earnings at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$14.59B+42.3%
Climb Global Solutions, Inc. logo
Climb Global Solutions, Inc.CLMB
$90.37M+26.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$1.51B-1.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$881.9M-71.9%
Vor Biopharma logo
Vor BiopharmaVOR
-$1.37B-180%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$825.44M-3.4%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.35B+436%
Enterprise value$1.3B+3,925%

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by Jade Biosciences in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:27 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212088
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Series A non-voting convertible preferred stock, $0.0001 par value; 12,622 shares authorized as of both March 31, 2026 and December 31, 2025; 12,622 shares issued and outstanding as of both March 31, 2026 and December 31, 202522
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 49,345,967 and 49,316,287 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively55
Additional paid-in capital511,554506,771
Accumulated other comprehensive (loss) income(342)129
Accumulated deficit(214,757)(174,389)
Total stockholders’ equity296,462332,518
Total liabilities and stockholders' equity$319,433$349,781

Item 1. Financial Statements.

FAQ

What is Jade Biosciences's retained earnings?
Jade Biosciences (JBIO) reported retained earnings of -$214.76M in Q1 2026.
How has Jade Biosciences's retained earnings changed year-over-year?
Jade Biosciences's retained earnings increased by 8.8% year-over-year, from -$235.57M to -$214.76M.
What is the long-term trend for Jade Biosciences's retained earnings?
Over 5 years (2020 to 2025), Jade Biosciences's retained earnings has grown at a 67.0% compound annual growth rate (CAGR), from -$13.41M to -$174.39M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Jade Biosciences's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude